Results 171 to 180 of about 62,490 (297)
Nanoclay‐Engineered Scaffolds for the Controlled Delivery of Biomolecules in Regenerative Medicine
Asia-Pacific Journal of Chemical Engineering, EarlyView.ABSTRACT Regenerative medicine combines biomaterials, cells, scaffolds, and bioactive agents via modern technologies to aid in the reconstruction and repair of damaged tissues. Among these, nanoclay scaffolds have demonstrated unique advantages in facilitating the delivery of therapeutic agents.
Mehri Shadi +2 more
wiley +1 more source
Percutaneous cholecystostomy in acute acalculous cholecystitis [PDF]
, 1989 Arbogast, Helmut +3 more
core +1 more source
Animal Research and One Health, EarlyView.The aim of our study is to evaluate the interaction between HS and the incorporation of PKM in broiler chicken diets, as well as its effect on growth performance and metabolism. Based on the results obtained, PKM supplementation failed to mitigate the adverse effects of heat stress in broiler chickens. ABSTRACT The aim of this study was to evaluate the
Ahmed Mijiyawa +13 more
wiley +1 more source
Paediatric development of radiopharmaceutical imaging agents and radioligand therapeutics
British Journal of Clinical Pharmacology, EarlyView.Abstract This review focuses on the development of radiopharmaceutical imaging agents and radioligand therapeutics for paediatric use. Nuclear medicine plays an important role in the diagnosis and treatment of various childhood conditions, including cancers, infections and brain disorders.
Justin L. Hay +5 more
wiley +1 more source
British Journal of Clinical Pharmacology, EarlyView.Aim Fluorescence‐guided surgery enhances intraoperative visualization of anatomical structures. Nizaracianine is a near‐infrared fluorescent agent that is exclusively renally cleared in animal models. It enables real‐time ureteral imaging and identification, potentially reduces risk of injury and facilitates assessment before surgical closure.
Lisanne K. A. Neijenhuis +5 more
wiley +1 more source
British Journal of Clinical Pharmacology, EarlyView.Aim Elexacaftor/tezacaftor/ivacaftor (ETI) has markedly improved cystic fibrosis (CF) outcomes. However, its long‐term impact on nutrition, metabolism and liver health remains underexplored. We assessed 30‐month changes in pulmonary, nutritional, metabolic and inflammatory markers in people with CF (PwCF) homozygous for F508del.
Nicola Perrotta +5 more
wiley +1 more source